STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction
STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within 6-24 Hours or Rescue Coronary Intervention Versus a Strategy of Standard Primary PCI in Patients With Acute Myocardial Infarction Within 3 Hours of Onset of Symptoms
Sponsor: Boehringer Ingelheim
A PHASE3 clinical study on Myocardial Infarction, this trial is completed. The trial is conducted by Boehringer Ingelheim and has accumulated 7 data snapshots since 2008. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Sep 2019 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Mar 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alexandroupoli, Greece , Almería, Spain , Ambérieu-en-Bugey, France , Athens, Greece , Aubervilliers, France , Belfast, United Kingdom , Belgrade, Serbia , Berlin, Germany , Besançon, France , Bobigny, France and 100 more locations